Study Population
death
COMPLICATIONS
The Convalescent Plasma to Limit SARS-CoV-2 Associated Complications (CSSC-004) trial was a double-masked, multicenter, randomized, controlled trial investigating the use of CCP to prevent hospitalization and death among outpatients, compared with control plasma [